Program
Leucovorin
Also written as “leucovorin”, “Folinic acid” and “FLOT Chemotherapy”.
Its studies are mostly in Colorectal Neoplasms · Neoplasms · Pancreatic Neoplasms · Carcinoma, Hepatocellular · Stomach Neoplasms, led by 21 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 50 open or running | phase 3since May 9, 2007 | May 9, 2007 | none ahead |
| AstraZeneca | 41 open or running | phase 2since Jul 17, 2003 | Jul 17, 2003 | Nov 9, 2027phase 2 · NCT07069712 |
| Bristol-Myers Squibb | 40 open or running | phase 2since Jun 26, 2002 | Jun 26, 2002 | none ahead |
| Hoffmann-La Roche | 30 open or running | phase 2since Feb 26, 2010 | Feb 26, 2010 | none ahead |
| Pfizer | 21 open or running | phase 3since Sep 1, 2005 | Sep 1, 2005 | none ahead |
| 3SBio | 11 open or running | phase 2since Jun 25, 2024 | Jun 25, 2024 | none ahead |
| AbbVie | 11 open or running | phase 2since Oct 25, 2023 | Oct 25, 2023 | Dec 2026phase 2 · NCT06107413 |
| adherex-technologies-inc | 10 open or running | phase 2since Oct 27, 2010 | Oct 27, 2010 | none ahead |
| Aurobindo Pharma | 10 open or running | phase 2since Mar 28, 2014 | Mar 28, 2014 | none ahead |
| Cardiff Oncology | 10 open or running | phase 2since Feb 9, 2021 | Feb 9, 2021 | none ahead |
| Eli Lilly | 10 open or running | phase 2since Jul 3, 2012 | Jul 3, 2012 | none ahead |
| Ipsen | 10 open or running | phase 3since Sep 6, 2019 | Sep 6, 2019 | none ahead |
| Jiangsu HengRui Medicine | 11 open or running | phase 3since Feb 20, 2023 | Feb 20, 2023 | none ahead |
| leaf-vertical-inc | 10 open or running | phase 2since Jun 5, 2018 | Jun 5, 2018 | none ahead |
| Merck KGaA, Darmstadt, Germany | 10 open or running | phase 3since Dec 4, 2015 | Dec 4, 2015 | none ahead |
| Merrimack Pharmaceuticals | 10 open or running | phase 3since Dec 14, 2011 | Dec 14, 2011 | none ahead |
| Novartis | 10 open or running | phase 1since Jan 4, 2011 | Jan 4, 2011 | none ahead |
| oncolytics-biotech | 10 open or running | phase 1since Jan 7, 2011 | Jan 7, 2011 | none ahead |
| Swedish Orphan Biovitrum | 10 open or running | phase 2since Feb 14, 2006 | Feb 14, 2006 | none ahead |
| tty-biopharm | 10 open or running | phase 2since Apr 12, 2018 | Apr 12, 2018 | none ahead |
| wellstat-therapeutics | 10 open or running | phase 1since Sep 4, 2002 | Sep 4, 2002 | none ahead |
Also a collaborator on its studies: Ono Pharmaceutical, parexel, Halozyme Therapeutics, biolinerx-ltd, axis-clinicals-limited and Regeneron Pharmaceuticals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 20 studies since Jun 26, 2002.
- Mar 28, 2014Aurobindo Pharma's first study: phase 2 study in Lymphoma, T-Cell, PeripheralNew to Aurobindo PharmaAurobindo Pharma · NCT02106650 · 36 enrolled · United States
- Dec 4, 2015Merck KGaA, Darmstadt, Germany's first study: phase 3 study in Neoplasm MetastasisNew to Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany · NCT02625610 · 499 enrolled · United States, Australia, Brazil and more
- Jun 9, 2017Phase 2 study in Colorectal NeoplasmsBristol-Myers Squibb · NCT03184870 · 332 enrolled · United States, Australia, Belgium and more
- Sep 11, 2017Phase 2 study in Esophageal NeoplasmsHoffmann-La Roche · NCT03281369 · 219 enrolled · United States, Australia, Israel and more
- Nov 6, 2017Phase 2 study in Advanced Pancreatic CancerBristol-Myers Squibb · NCT03336216 · 205 enrolled · United States, Canada, Denmark and more
- Apr 12, 2018tty-biopharm's first study: phase 2 study in Colorectal NeoplasmsNew to tty-biopharmtty-biopharm · NCT03517618 · 41 enrolled · Taiwan
- Jun 5, 2018leaf-vertical-inc's first study: phase 2 study in Pancreatic NeoplasmsNew to leaf-vertical-incleaf-vertical-inc · NCT03607643 · 160 enrolled · United States
- Sep 6, 2019Ipsen's first study: phase 3 study in Metastatic Adenocarcinoma of the PancreasNew to IpsenIpsen · NCT04083235 · 770 enrolled · United States, Australia, Austria and more
- Oct 5, 2020Phase 3 study in NeoplasmsPfizer · NCT04607421 · 841 enrolled · United States, Argentina, Australia and more
- Feb 9, 2021Cardiff Oncology's first study: phase 2 study in Pancreatic Ductal AdenocarcinomaNew to Cardiff OncologyCardiff Oncology · NCT04752696 · 41 enrolled · United States
- Feb 20, 2023Jiangsu HengRui Medicine's first study: phase 3 study in First-line Treatment of Advanced Pancreatic CancerNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT05751850 · 778 planned · China
- Oct 25, 2023AbbVie's first study: phase 2 study in NeoplasmsNew to AbbVieAbbVie · NCT06107413 · 280 enrolled · United States, Belgium, Germany and more
- Jun 25, 20243SBio's first study: phase 2 study in Colorectal NeoplasmsNew to 3SBio3SBio · NCT06493760 · 130 planned · China
- Jun 24, 2025Phase 2 study in Stomach NeoplasmsAstraZeneca · NCT07069712 · 100 planned · United States, Canada, China and more
Ahead
- Dec 2026Primary completion: phase 2 study in NeoplasmsAbbVie · NCT06107413
- Nov 9, 2027Primary completion: phase 2 study in Stomach NeoplasmsAstraZeneca · NCT07069712
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07069712Stomach Neoplasms · United States, Canada, China and more | 2 | Recruiting | AstraZeneca | Nov 9, 2027 | 100 |
| NCT06493760Colorectal Neoplasms · China | 2 | Recruiting | 3SBio | Jun 2025 | 130 |
| NCT06107413Neoplasms · United States, Belgium, Germany and more | 2 | Active, not recruiting | AbbVie | Dec 2026 | 280 |
| NCT05751850First-line Treatment of Advanced Pancreatic Cancer · China | 3 | Recruiting | Jiangsu HengRui Medicine | Dec 30, 2024 | 778 |
| NCT04752696Pancreatic Ductal Adenocarcinoma · United States | 2 | Terminated | Cardiff Oncology | Dec 24, 2024 | 41 |
| NCT04607421Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Mar 1, 2025 | 841 |
| NCT04083235Metastatic Adenocarcinoma of the Pancreas · United States, Australia, Austria and more | 3 | Completed | Ipsen | Jul 23, 2022 | 770 |
| NCT03607643Pancreatic Neoplasms · United States | 2 | UNKNOWN | leaf-vertical-inc | Jun 30, 2020 | 160 |
| NCT03517618Colorectal Neoplasms · Taiwan | 2 | Completed | tty-biopharm | Jun 18, 2015 | 41 |
| NCT03336216Advanced Pancreatic Cancer · United States, Canada, Denmark and more | 2 | Completed | Bristol-Myers Squibb | Jun 1, 2023 | 205 |
| NCT03281369Esophageal Neoplasms · United States, Australia, Israel and more | 2 | Terminated | Hoffmann-La Roche | Oct 9, 2025 | 219 |
| NCT03184870Colorectal Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Bristol-Myers Squibb | Apr 6, 2023 | 332 |
| NCT02625610Neoplasm Metastasis · United States, Australia, Brazil and more | 3 | Completed | Merck KGaA, Darmstadt, Germany | Sep 13, 2019 | 499 |
| NCT02106650Lymphoma, T-Cell, Peripheral · United States | 2 | Completed | Aurobindo Pharma | Oct 2018 | 36 |
| NCT01930552Neoplasms · China | 1 | Completed | Sanofi | Dec 2014 | 20 |
| NCT01634555Solid Tumors · United States | 2 | Completed | Eli Lilly | Aug 2013 | 29 |
| NCT01494506Pancreatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Merrimack Pharmaceuticals | Feb 2014 | 417 |
| NCT01274624Neoplasms · United States | 1 | Completed | oncolytics-biotech | Feb 2018 | 36 |
| NCT01271166Neoplasms · Australia | 1 | Terminated | Novartis | Aug 2009 | 10 |
| NCT01231802Breast Neoplasms · United States, Russian Federation | 2 | UNKNOWN | adherex-technologies-inc | Aug 2012 | 140 |
| NCT01227707Colorectal Neoplasms · Italy | 2 | Completed | Hoffmann-La Roche | Aug 2010 | 43 |
| NCT01077739Colorectal Neoplasms · Belgium | 2 | Completed | Hoffmann-La Roche | Jan 2012 | 75 |
| NCT01046864Pyloric Stenosis, Hypertrophic · United States, Canada, France | 1 | Completed | Bristol-Myers Squibb | Jun 2014 | 49 |
| NCT00782041Uterine Neoplasms · Thailand | 2 | Terminated | Sanofi | Aug 2003 | 11 |
| NCT00559455Carcinoma, Hepatocellular · Korea, Republic of | 2 | Completed | Sanofi | Jan 2010 | 38 |
| NCT00499850Adenocarcinoma · Australia | 1 | Completed | Sanofi | Jun 2006 | 18 |
| NCT00471965Carcinoma, Hepatocellular · China, Korea, Republic of, Taiwan and more | 3 | Completed | Sanofi | Mar 2010 | 371 |
| NCT00291785Colorectal Neoplasms · Italy | 2 | Completed | Swedish Orphan Biovitrum | Aug 2007 | 48 |
| NCT00237900Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC · Finland | 2 | Terminated | AstraZeneca | 34 | |
| NCT00233623Colorectal Neoplasms · Italy | 2 | Withdrawn | AstraZeneca | Jan 2006 | 190 |
| NCT00143403Colorectal Neoplasms · Belgium, Denmark, France and more | 3 | Completed | Pfizer | Feb 2008 | 321 |
| NCT00065117Colorectal Neoplasms · United States | 2 | Terminated | AstraZeneca | Feb 2004 | 180 |
| NCT00044785Colorectal Neoplasms · United States | 1 | Terminated | wellstat-therapeutics | 24 | |
| NCT00040391Colorectal Neoplasms · United States | 2 | Terminated | Bristol-Myers Squibb |
How it is read
Names in the registry
- “Leucovorin”, 18 entries
- “leucovorin”, 4 entries
- “Folinic acid”, 3 entries
- “FLOT Chemotherapy”, 1 entry
- “Folinic Acid”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 12 studies
- Neoplasms, 4 studies
- Pancreatic Neoplasms, 4 studies
- Carcinoma, Hepatocellular, 2 studies
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.